Submitted by Sabin on
NEW CANAAN, CT—Robert H. Abplanalp, a major sponsor of the Albert B. Sabin Vaccine Institute, died August 30 at his home in Bronxville, NY. He was 81 years old and had cancer.
Submitted by Sabin on
NEW CANAAN, CT—Treatment options for a variety of cancers are expanding to include an array of exciting new approaches. Along with well-established companies, newer biotechnology and biopharmaceutical firms are looking to break into an emerging market that would provide vaccines for both solid cancers—such as melanoma, prostate, breast, lung, cervical, colon, brain, and ovarian—and blood borne cancers—such as lymphoma, leukemia, and myeloma.
Submitted by Sabin on
WASHINGTON, D.C.— Two recent studies released by the WASHINGTON, D.C.— Two recent studies released by the American Journal of Preventive Medicine and the
Submitted by Sabin on
NEW CANAAN, CT—The Sabin Vaccine Institute presents its highest non-science awards on May 14 to four illustrious groundbreakers in business, social service, and academia. One is the leader of one of the world’s premier pharmaceutical companies, two are collaborators in starting an organization to benefit the nation’s medically underserved children, and a fourth is a prominent university president.
Submitted by Sabin on
NEW CANAAN, CT— Cancer vaccines present an elusive goal, yet one that is increasingly within reach for biomedical researchers. Their hope is to offer physicians and cancer patients more and better therapy options than radiation and chemotherapy.